CALR EXON 9 FRAMESHIFT

CI-VAR-00000890Explore in graph →CIViC 559

Curated evidence

Evidence by cancer (7 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–7 of 7 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Essential Thrombocythemia3
CALR EXON 9 FRAMESHIFT	(prognostic)	Prognostic	B	Supports Better Outcome	3	submitted	EID6387 In a study of 402 patients with essential thrombocythemia, 227 harbored JAK2 mutations and 114 harbored CALR mutations (51 type 1 L367fs46 and 44 type 2 K385fs47). Overall survival did not differ be… (full text at CIViC) PMID 24753125 · Tefferi et al., 2014 · Open in CIViC	civic
CALR EXON 9 FRAMESHIFT	(prognostic)	Prognostic	B	Does Not Support Poor Outcome	2	submitted	EID6389 In the subset of patients with essential thrombocythemia (including potential unidentified prefibrotic stage of myelofibrosis), patients with type 1 L367fs*46 mutations (N=111) had no significant diff… (full text at CIViC) PMID 25212275 · Cabagnols et al., 2015 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Primary Myelofibrosis4
CALR EXON 9 FRAMESHIFT	(prognostic)	Prognostic	A	Supports Better Outcome	4	accepted	EID1387 Study of 428 patients with primary Myelofibrosis found that those patients harboring CALR exon 9 mutations displayed significantly longer survival than those with JAK2 mutations (HR: 2.5, median survi… (full text at CIViC) PMID 25037629 · Tefferi et al., 2014 · Open in CIViC	civic
CALR EXON 9 FRAMESHIFT	(prognostic)	Prognostic	B	Supports Better Outcome	4	accepted	EID1649 In patients with primary myelofibrosis CALR mutations were associated with improved median survival. For 277 patients, CALR mutated, ASXL1 wildtype patients (median survival, 10.4 years, N=46); CALR w… (full text at CIViC) PMID 24496303 · Tefferi et al., 2014 · Open in CIViC	civic
CALR EXON 9 FRAMESHIFT	(prognostic)	Prognostic	B	Supports Better Outcome	3	submitted	EID6386 In a study of 617 patients with primary myelofibrosis, 140 CALR-mutated patients harboring the type 1 (N=101, 52-bp deletion L367fs46), the type 2 mutation (N=22, 5-bp insertion K385fs47) or other i… (full text at CIViC) PMID 24986690 · Rumi et al., 2014 · Open in CIViC	civic
CALR EXON 9 FRAMESHIFT	(prognostic)	Prognostic	B	Supports Poor Outcome	2	submitted	EID6388 In the subset of patients with myelofibrosis (including primary myelofibrosis and post-essential thrombocythemia MF), (including PMF and post-ET MF), patients with type 1 mutations (N=33) had poorer o… (full text at CIViC) PMID 25212275 · Cabagnols et al., 2015 · Open in CIViC	civic